Ruzasvir

DB11713InvestigationalSmall molecule

Ruzasvir has been used in trials studying the treatment of Hepatitis C, Hepatitis C, Chronic, and Hepatitis C Infection.

Mechanism: Pharmacologically active on Nonstructural protein 5A
Curator reviewed
Formula / weight: C₄₉H₅₅FN₁₀O₇S · 947.1 g/mol (avg)
Code names: AT-038 · MK-8408

Resolves to

Compound

UNIILX752BD95YCAS1613081-64-3ChEMBLCHEMBL3971095PubChem91936863

Structure

InChIKeyAXWDHVUJXNOWCC-RAEGKSCOSA-NSMILES

COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C2N3[C@@H](OC4=C(C3=CC2=C1)C(F)=CC(=C4)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C)C1=CN=C(S1)C1CC1

Targets

Q5L478NS5A

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

14Drug interactionsStructured to mechanism, not free text

11Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ruzasvir, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account